Phaseline

Companies › Tridem Bioscience FlexCo

Tridem Bioscience FlexCo: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TRB-001
alpha-synuclein (aSyn) vaccine
–Phase 1Parkinson's Disease; Parkinson Disease (PD)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07777484TRB-001Phase 1Parkinson's DiseaseNeurologyDec 2026
NCT07840027TRB-001Phase 1Parkinson Disease (PD)NeurologySep 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.